Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 26026 results found since Jan 2013.
Decipher the Biology of Lethal Prostate Cancer —Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
Condition: Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients Intervention: Other: No intervention required Sponsor: National Taiwan University Hospital Not yet recruiting - verified July 2017
Source: ClinicalTrials.gov - July 30, 2017 Category: Research Source Type: clinical trials
CT-Guided Irreversible Electroporation for Locally Recurrent Prostate Cancer following Radical Prostatectomy and Salvage Radiation Therapy
Publication date: September 2017 Source:Journal of Vascular and Interventional Radiology, Volume 28, Issue 9 Author(s): Bernhard Gebauer, Judith Enders, Alexander D.J. Baur, Bernd Hamm, Federico Collettini
Source: Journal of Vascular and Interventional Radiology - August 24, 2017 Category: Radiology Source Type: research
Bladder Protection with Continuous Infusion of Warmed Saline Solution to Facilitate CT-Guided Cryoablation of Prostate Cancer with Extracapsular and Bladder Invasion
Publication date: September 2017 Source:Journal of Vascular and Interventional Radiology, Volume 28, Issue 9 Author(s): J. Matthew Meadows, Jeffrey Forris Beecham Chick, Joseph J. Gemmete, Matthew S. Davenport, Ravi N. Srinivasa
Source: Journal of Vascular and Interventional Radiology - August 24, 2017 Category: Radiology Source Type: research
The unidirectional hypoxia ‐activated prodrug OCT1002 inhibits growth and vascular development in castrate‐resistant prostate tumors
ConclusionsThese studies provide the first evidence that OCT1002 can be an effective agent in treating hypoxic, castrate‐resistant prostate tumors, either singly or in combination with established chemotherapeutics for prostate cancer.
Source: The Prostate - September 25, 2017 Category: Urology & Nephrology Authors: Heather Nesbitt, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown, Declan J. McKenna Tags: ORIGINAL ARTICLE Source Type: research
Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy
In this study Leapman et al analyze upgrading diagnostic biopsy Gleason scores after pathological review of radical prostatectomy specimens in 895 men with low risk prostate cancer in the SEARCH (Shared Equal Access Regional Cancer Hospital) database. Low risk was defined as Gleason pattern 3 + 3 or less on diagnostic bio psy, prostate specific antigen (PSA) 10 ng/ml or less and clinical stage T2a or less.
Source: The Journal of Urology - September 26, 2017 Category: Urology & Nephrology Authors: Lance K. Heilbrun, Isaac J. Powell Tags: Letter to the Editor/Errata Source Type: research
